VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

• click to rate

  Posted by Two Blokes May 28 - Filed in Stock - 0 views
  
  Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.